SCHEMBL16362084

SCHEMBL16362084

Cc1c(-c2ccc(NC(=O)c3c(F)cccc3F)cn2)ccc2c1oc(=O)n2C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IL2 P60568 10/20 0.48
▸ TNF P01375 1/20 0.48
▸ STIM1 Q13586 1/20 0.48
▸ ORAI1 Q96D31 1/20 0.48
▸ RAB9A P51151 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ LMNA P02545 1/20 0.40
▸ CRACR2A Q9BSW2 1/20 0.40
▸ GRM1 Q13255 1/20 0.38
▸ GRM4 Q14833 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ NOD2 Q9HC29 1/20 0.37
▸ CDK1 P06493 2/20 0.37
▸ CDK2 P24941 2/20 0.37
▸ CCNB1 P14635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16362416 0.88 IL2 (0.49) IL2TNFSTIM1ORAI1RAB9A
SCHEMBL17766375 0.88 IL2 (0.48) IL2TNFSTIM1ORAI1RAB9A
SCHEMBL16361888 0.87 IL2 (0.57) IL2TNFSTIM1ORAI1MEN1
SCHEMBL16362395 0.87 CRACR2A (0.47) IL2TNFSTIM1ORAI1RAB9A
SCHEMBL16361887 0.85 IL2 (0.62) IL2TNFSTIM1ORAI1MEN1
SCHEMBL16362400 0.84 IL2 (0.49) IL2TNFSTIM1ORAI1RAB9A
SCHEMBL16321557 0.83 IL2 (0.49) IL2TNFSTIM1ORAI1RAB9A
SCHEMBL16362087 0.82 IL2 (0.50) IL2TNFSTIM1ORAI1RAB9A
SCHEMBL17766347 0.80 IL2 (0.59) IL2TNFSTIM1ORAI1RAB9A
SCHEMBL16362056 0.80 IL2 (0.58) IL2TNFSTIM1ORAI1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US claimed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US claimed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
WO-2014203217-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2014-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS RYR2, NR2C2, CACNA1E IL2 2831/4885TNF 3546/4885STIM1 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback